Michael Fernando and Josh Hurwitz
Oncology for the Inquisitive Mind
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for more information.
Be sure to visit the podcast's website and support the creator: www.inquisitiveonc.com
Author
Michael Fernando and Josh Hurwitz
Category
Podcast website
Latest episode
Nov 17, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
147. Back to Basics - Metastatic Triple Negative Breast Cancer 01.03.2025 19:18
Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway! Studies discussed in the episode: KEYNOTE 355 ASCENT For more episodes, resources and...
146. Back to Basics - BRCA mutation and Breast Cancer Management 22.02.2025 24:43
It's been an "Olympic" ride to get here, and this is our penultimate breast cancer episode! Today, we talk about the BRCA mutations and how they impact both breast cancer and outcomes using targeted therapy. BRCA is a tumour suppressor gene. Today, we explore olaparib and its role in the adjuvant and metastatic setting for breast cancer. Studies discussed in the episode: OLYMPIA OLYMPIAD For more...
145. Back to Basics - Metastatic Hormone Receptor Positive Breast Cancer 15.02.2025 19:41
Metastatic Hormone Receptor-Positive Breast Cancer truly represents the frontier of Medical Oncology, with life expectancy creeping up to and beyond five years. This week, we discuss Monaleesa-2 (Ribociclib), Paloma-2 (Palbociclib) and, of course, highlight the importance of Monarch-3 (Abemaciclib). The great CDK debate continues, and while the phase three trials have a clear winner, it's importan...
144. Back to Basics - Early Triple Negative Breast Cancer 08.02.2025 25:49
Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers. This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of...
143. San Antonio Breast Cancer Symposium 2024 - Part 2 01.02.2025 20:57
Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024. In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel ADC (SHR-A1811) and the role of tumour mutational burden in triple-negative cancer. Studies discussed in the episode: DESTINY-Breast06...
142. San Antonio Breast Cancer Symposium 2024 - Part 1 26.01.2025 28:06
Welcome back to Oncology for the Inquisitive Mind, where we head back to late 2024 and cover some pivotal trials and ideas from the San Antonio Breast Cancer Conference 2024. This episode broadly covers hormone receptor-positive breast cancer and looks at another CDK comparison (real-world data). While the idea is not new, the potential implications from well-gathered "phase 4" data is a curious d...
141. Back to Basics - The role of endocrine therapy in Breast Cancer 21.12.2024 24:04
Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal improvement in the adjuvant breast cancer space. How long should one take endocrine therapy? We cover all the facts you need to...
140. Back to Basics - Adjuvant HER2 Breast Cancer (Part 2) 14.12.2024 19:21
HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditio...
139. Back to Basics - Early HER2 Breast Cancer 08.12.2024 24:31
Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood. This week, we explore the original wonder drug (Trastuzumab) in the early brea...
138. Back to Basics - Adjuvant CDK4/6 inhibitors in Early Breast Cancer 30.11.2024 22:50
Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemacicl...
137. Back to Basics - High Risk Breast Cancer 23.11.2024 26:40
Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and Michael look at one of the practice-changing papers that tried to address how to manage high-risk patients. This study is called Soft and Text. It asked if adding ovarian suppression to aromatase inhi...
136. Evolving landscape of Genitourinary Cancers (Bladder Cancer) - Prof Enrique Grande 16.11.2024 39:06
Prof Enrique Grande, a medical oncologist from Madrid, Spain, is our guest on Oncology for the Inquisitive Mind this week. Enrique is not your average oncologist nor your average podcast guest with a fascinating back story, a varied career and the charisma and wisdom to match! Enrique has worked in all facets of oncology, including industry and is helping transform how patients access oncology car...
135. ESMO 2024 - Breast Cancer with Dr Adam Brufsky 09.11.2024 28:24
In our final ESMO 2024 analysis this week, we bring back Dr. Adam Brufsky, "a giant among men (and women)" in breast cancer research and management. He discusses the field, the pivotal updates in ESMO, and what this means for patients. He also explores many of the unanswered questions. Links to studies discussed in this episode (subscription may be required): DESTINYBREAST012 KEYNOTE522 Many other...
134. ESMO 2024 - Lung Cancer with Dr Ned McNamee 02.11.2024 30:15
Lung cancer treatment has changed seismically since 2018 and the NEJM publication of Keynote 189. This week, we have Dr. Ned Mcnamee on the show to give us his highlights of lung cancer updates from ESMO 2024. He explores the resectable lung cancer space with Checkmate-77T; crosses the ADRIATIC trial in patients with limited-stage small cell lung cancer, and brings in a home run with an updated LA...
133. ESMO 2024 - Genitourinary Cancers with Prof Anthony Joshua 26.10.2024 31:12
ESMO 2024 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings their greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best th...
132. ESMO 2024 - Colorectal Cancer with Dr Geoffrey Chong 19.10.2024 18:17
With ESMO 24 firmly in the rearview mirror, the dust settling, and the end of the year closing in, Michael and Josh take one final look at the trials that may change practice, direct research, or are just generally interesting. This week, we interviewed Dr Geoffrey Chong, a medical oncologist specialising in gastrointestinal cancers who currently holds appointments at the Olivia Newton-John Cancer...
131. ESMO 2024 - Plenary Special 18.09.2024 37:07
We have finally come to the end of ESMO 2024, and as is now tradition, Michael and Josh conclude their epic journey with a special episode highlighting their absolute favourite practice-changing selections from the Plenary Sessions. As always, ESMO brought a selection of wonderful studies that truly deserve the title "practice changing." As always, a huge thanks to everyone who joined us on this a...
130. ESMO 2024 - Day 4 17.09.2024 32:25
The end of the road approaches, and ESMO 2024 will soon be in the rearview mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO. Studies discussed in this episode: Biomarker analysis of PEACE-1 ARA...
129. ESMO 2024 - Day 3 16.09.2024 22:45
Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy. They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive pr...
128. ESMO 2024 - Day 2 15.09.2024 30:06
Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supp...
127. ESMO 2024 - Day 1 14.09.2024 24:06
The European Society of Medical Oncology Congress has begun, and Michael and Josh are on the ground, bringing you breaking studies and heartbreaks along with some important updates in the science and art of medical oncology. Michael and Josh cover a range of tumour types on day one, a slight deviation from our regular coverage. They look at hepatocellular carcinoma, renal cancers, and breast cance...
126. Ocular Melanoma and Prostate Cancer with A/Prof Anthony Joshua 24.08.2024 41:12
Oncology for the Inquisitive Mind has been privileged to interview some truly brilliant specialists, and this week's guest is no exception. Professor Anthony Joshua is the Head of Oncology at the Kinghorn Cancer Centre and St Vincent's Health in Sydney. He is a globally recognised expert in genitourinary cancers and melanoma, with a special interest in ocular melanoma. Professor Joshua completed h...
125. Spotlight - Biotech ImmVirX with Dr Malcolm McColl and Prof Darren Shafren 17.08.2024 37:29
Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used i...
124. Metastatic HER2- positive breast cancer 10.08.2024 30:40
Metastatic HER2-positive breast cancer continues to dominate headlines, and new therapeutic options continue to be found for those afflicted with the disease. Before trastuzumab (anti-HER2 therapy), the overall survival for this cohort of patients was less than two years. As technology and treatments changed, it can boast an extended survival well beyond five years in numerous studies, with many p...
123. Spotlight: MARIPOSA for EGFRmut Lung Cancer 03.08.2024 25:33
The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for the likes of alectinib, lorlatinib and sotorasib to carve out niches for their own driver mutations. However, the...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.